PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
| Autor: | R. Perez-Santamarina, X. Badia, José Luis Poveda, M. Tort, José Antonio Vinagre Romero, J.L. Trillo, M.T. Álvarez, Amparo Santamaría, I. Cuervo-Arango |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Emicizumab
business.industry Health Policy Haemophilia A Public Health Environmental and Occupational Health Multiple-criteria decision analysis medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Medicine Operations management business Value (mathematics) 030217 neurology & neurosurgery |
| Zdroj: | Value in Health. 21:S462-S463 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2018.09.2729 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect